SNAPSHOT

Mission:
- To introduce the first FDA approved evidence-based test for depression/anxiety
- Present an objective test for evaluating the efficacy of treatment for mental illness
- Develop an monetise an objective test to measure stress

Vision:
- Early entrant in the transformation of Healthcare by technology (Digital Health)

Strategic Partners:
- Johns Hopkins University and the Black Dog Institute
- World leaders in mental health research

Market:
- Depression diagnostic alone is a US$16bn revenue opportunity – “large”

Timeline:
- First revenue via corporate stress-test products targeted H2 2015
- Johns Hopkins validation study completed in 8-10 months
- Targeting FDA Approval within 12 months from completion of study

Valuation:
- Capitalisation $25m with $2m in cash
- 90M shares @ $0.275
MENTAL HEALTH LANDSCAPE

350 Million Worldwide Diagnosed With Depression
1 Suicide Every 40 Seconds

1 Million Suicides Every Year

26% of Adult Population
1 in 10 on Antidepressants
US $10Bn Spent annually

27% of Adult Population

20% of Adult Population

Global Cost US$2.5T (2030 est. US$6T) — Depression and Anxiety account for +50% of this burden

http://www3.weforum.org/docs
LONG TERM VISION – MEDTECH FOR MENTAL HEALTH AND STRESS

- World’s first Digital Health Diagnostics Platform specialising in the analytics of ECG data focused on Stress and Mental Health
- Digital Health: Hardware agnostic for the collection of ECG Data
- Allowing for global access to all payers in the Health, Occupational Health, Wellbeing, and E-Health space
- Monetise each segment of the market and diversify the potential client base:
  - Medical Diagnostics
  - Remote Patient Monitoring
  - Corporate Wellness/Elite Sports
  - Wearables/Consumer Apps
- Hardware is not our core business
- Become a data play which adds value based on a secure HIPAA\(^{(1)}\) protected analytics platform with the largest collection of clean ECG data sets worldwide

<table>
<thead>
<tr>
<th>Timing</th>
<th>Milestone</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 2014</td>
<td>Australian and US validation studies (BDI &amp; JHU)</td>
<td>✓</td>
</tr>
<tr>
<td>Q1 2015</td>
<td>Delivery of Commercialisation Study (AMETUS)</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Establish World-Class Advisory Board (Dr Prendergast)</td>
<td>✓</td>
</tr>
<tr>
<td>Q2 2015</td>
<td>Acquisition remaining patents covering the technology (USA/Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Complete beta testing of Stress Algorithms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Strategic Device Partner</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Announcement of foundation customers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pre-submission package delivered to the FDA and FDA feedback</td>
<td></td>
</tr>
<tr>
<td>Q3 2015</td>
<td>Complete development of Corporate Stress product</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Commercial launch of Corporate Stress product</td>
<td></td>
</tr>
<tr>
<td>Q4 2015</td>
<td>Results from U.S./Australian validation studies published</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Commercial launch of Consumer Stress App (subject to device)</td>
<td></td>
</tr>
</tbody>
</table>
• There is no objective test for mental illness

• The diagnostic “gold standard” is a clinical/expert opinion

• Diagnostic agreement between clinicians can vary considerably even for high prevalence disorders like depression and anxiety

• Circadian Heart Rate (CHR) analysis adds an objective dimension to the diagnosis of depression/anxiety and the evaluation of treatment

• The late, under/over, and misdiagnosis of depression (and other mental illness) places a huge cost burden on the healthcare system and the workplace

• CHR can add an objective dimension to screening for depression and anxiety

“It is critical to realise that we cannot succeed if we use DSM categories as the gold standard” - “We need a quantitative method for diagnosing depression”

(U.S. National Institute of Mental Health - May 2013)
OUR SOLUTION

- Quantitative, objective test
- Diagnosis based on biological data (circadian heart rate)
- Simple, safe and unobtrusive
- Gives objective indication of therapeutic effectiveness
- Earlier diagnosis enables earlier intervention
- Improved monitoring helps to optimize effective treatment
- Savings to the health system from earlier diagnosis

“The need for screening for and early detection of depression in primary care services is unarguable”
(World Federation for Mental Health)
• The autonomic nervous system (ANS) plays a key role in circadian sleep-wake regulation of physiological activity including heart rate

• It is well known that mental illness is associated with disturbances in ANS/circadian regulation

• Mental state-linked ANS disturbance is observed via the cardiovascular system, particularly during sleep when external influences are absent

• Therefore an analysis of CHR gives objective indications of ‘core’ physiological differences between broadly different forms of mental illness such as anxiety and depression and stress
• Based on over 15 years of research

• Different forms of mental illness such as anxiety and depression are associated with distinctly different patterns of CHR-V

• Distinct ‘biomarkers’ in heart rate data for depression and certain other mental illnesses have been identified

• CHR is ‘state-dependent’ - a change in clinical status is associated with a change in CHR patterns

• Serial monitoring of patients under psychiatric treatment has shown that:
  – effective treatment is associated with normalisation of CHR-V
  – ineffective treatment does not show normalisation
  – provides a tool for determining the effectiveness of treatment
STUDY OBJECTIVE
To validate the use of Medibio’s CHR technology to differentiate between depressed and non-depressed individuals
Designed to provide clinical data to support FDA certification of Medibio’s proprietary depression test

STUDY TIMELINE
Anticipated results published in Q4 2015

JOHN HOPKINS UNIVERSITY (JHU)
$7 billion integrated global health enterprise established in 1889
Ranked number one in the U.S. by US News & World Report for 22 years of the survey's 25-year history

PRINCIPAL RESEARCHER
DR NARESH PUNJABI
Professor of Medicine and Epidemiology in the Division of Pulmonary and Critical Care Medicine
Associate Director of Graduate Training Program in Clinical Investigation at JHU
Bloomberg School of Public Health
Published more than 100 research papers
To demonstrate that Medibio’s CHR Technology can distinguish between melancholic and non-melancholic depression.

Anticipated results published in Q4 2015

AUSTRALIA’S PREEMINENT MENTAL HEALTH RESEARCH ORGANISATION.

• Over 150 research and clinical staff
• Focus on the rapid translation of mental health research into improved clinical practice

PROFESSOR GORDON PARKER

Founder of the Black Dog Institute and Officer of the Order of Australia

One of the world’s leading authorities on depression and bipolar disorder
A positive outcome in the BDI study would make a significant impact on the treatment of depression and improved patient outcomes. Why?

**MELANCHOLIC DEPRESSION**
*Type of Major Depressive Disorder (MDD)*

- Biological Condition

  *Will respond to medication and/or ECT*

**NON-MELANCHOLIC DEPRESSION**
*Psychosocial Condition*

  *Will respond better to Psychotherapy*

50% of cases do not respond to antidepressants. Medications do not change the precipitating event/stress, nor the inwards coping style, but may lessen the symptoms.

High rate of spontaneous remission - treatment response can be difficult.
THREE CLEARLY DEFINED MARKETS

**MEDICAL**
- Primary Care Physicians
- Psychiatrists
- Psychologists
- Therapists
- Counsellors
- Cardiologists

**CORPORATE**
- High Risk Occupations
- Insurance Companies
- Corporate Wellness
- Professions
- Elite Sports

**CONSUMER**
- AppStores
- Insurance Companies
- Digital Health Companies
MEDICAL DIAGNOSTIC MARKET

Clinician orders test

Secure Access to Diagnostic
Reporting and Analysis -
Anywhere/Anytime

No disruption to normal clinical work flow

CHR collected from Patient and
transmitted to HIPAA Compliant
Cloud Storage

CHR processed by machine learning algorithms
Biometric data stored in HIPAA Compliant Cloud

For personal use only
• Size of the Market in the US $2.35bn annually (Depression Only)

• US Market Research undertaken as part of the market validation study showed
  – (+90%) would use this test as a diagnostic once clinically proven and reimbursable
  – Confirmed two primary markets for the use of the technology
    ✓ Initial diagnosis
    ✓ Monitoring to gauge therapeutic intervention effectiveness
  – PCP’s likely first adopters of the technology as a diagnostic tool
  – Mental health clinicians would use it as an adjunct tool

• Identified a series of existing CPT™ codes and payment structures which are supportive of, and can be leveraged for, MEB’s business plan in the US

<table>
<thead>
<tr>
<th>Medicare</th>
<th>Private</th>
<th>Insurance</th>
<th>Assumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>93225 Recoding (Provider)</td>
<td>$26.87</td>
<td>$40</td>
<td></td>
</tr>
<tr>
<td>93226 Analysis with Report (Medibio)</td>
<td>$37.97</td>
<td>$57</td>
<td>$45</td>
</tr>
<tr>
<td>93227 Physician review &amp; Interpretation (Provider)</td>
<td>$26.87</td>
<td>$40</td>
<td></td>
</tr>
</tbody>
</table>
US MARKET

- 40 million in the US (+5,000 staff firms)
- 21.3 million US Government positions
- US$2.2Bn revenue potential annually

DEMAND IN THE US DRIVEN BY MANY FACTORS

- need to reduce health care spend
- social responsibility/OHS Requirements
- absenteeism, presenteeism (In a 3-month period, patients with depression miss an average of 4.8 workdays and suffer 11.5 days of reduced productivity)

THREE DISTINCTIVE CHANNELS

- Full service turn-key solution
- Licensing/sale and data analytics model
- White label

1. US CDC, 2. US Census
OUR CORPORATE STRESS OFFERING

ASSESSMENT
Enable employees to check their stress levels
Personal early warning system for people at risk
Prevention is better than cure

SUPPORT
Provide educational material and support based on their stress level
May recommend discussion with GP
Provide the ability to conduct on-going monitoring to check progress

EMPLOYER BENEFIT
Metrics on stress levels for job classes and types
Reduced absenteeism and increased productivity
Reduced claims and pressure on the health care systems

END TO END SOLUTION FOR CORPORATES
M-HEALTH CONSUMER APP MARKET

- 500 million smartphone owners using a healthcare app in 2015

- 1.7 Billion smartphone/tablet owners will have downloaded mobile health applications by 2018\(^1\)

- Currently 44,000 medical apps on the App Store

- The market for mobile health applications and associated devices will grow at a compound annual growth rate of 61% to reach $26 billion in revenue by 2017, according to a new report from Research and Markets.

- Apple/Mayo Clinic partnership with IOS8. The Goal? IPhone/Apple Watch that makes you healthier!

- NHS (and US Institutions) predict that by 2030 self diagnosis and medication will be a necessity to alleviate pressure from the health care system resulting in only the critically ill being admitted to a medical institution.

---

• 10% of the 44,000 Health Apps are related to stress/mental health:
  – 2538 results in the search for stress
  – 628 results for depression
  – 854 results for anxiety
  – 475 results for mental health

• Most Stress Apps are based on reducing tension via breathing, yoga, and relaxing sounds.

• All are more of a wellness product than stress identification and mental health management

• Mental health and depression Apps are mostly based on subjective DSM5 method

• None offer objective stress assessment based on extended research

ALL THE BUILDING BLOCKS ARE NOW IN PLACE

MEDIBIO
World leading Mental Health Diagnostics Service

- New Stress and Diagnostic algorithms developed - beta testing underway
- No data handling. Data transmitted direct to the cloud for cloud based processing
- Johns Hopkins Hospital and Black Dog Institute.
- Medical Market Assessment and Validation Study completed by (Ametus Group)
- FDA/TGA Submissions using NAMSA (Best in class regulatory consultants)
- Strategic Device Partnership
- Foundation customers for Corporate Stress Product
- Developed
- Delivery Platform
- Revenue
- Large Market
- Opinion Leaders
- Scalable
- Validation
**TIMELINE TO COMMERCIALISATION**

- **Dec 14**: Johns Hopkins Study
- **Mar 15**: US Validation Study
- **Jun 15**: Australian Validation Study
- **Dec 15**: Stress Product Launch
- **Mar 16**: FDA (approval Targeted within 12 months)
- **Jun 16**: First Revenue

Additional Studies:
- **Anxiety Panic Disorder Study**
  - Completion & Publication
  - FDA (approval Targeted within 12 months)
This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

Certain statements made in this presentation are forward-looking statements. These forward looking statements are not historical facts but rather are based on Medibio Limited’s current expectations, estimates and projections about the industry in which Medibio operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered at-risk statements. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Medibio, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Medibio cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Medibio only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made.

Medibio will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.
## APPENDIX 1 - CAPITAL STRUCTURE

<table>
<thead>
<tr>
<th>Shares Options</th>
<th>Shares</th>
<th>Options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Existing shareholders</strong></td>
<td>existing shareholders</td>
<td>35,148,974</td>
</tr>
<tr>
<td><strong>Existing Convertible Notes</strong></td>
<td>30 series &quot;A&quot;</td>
<td>15,000,000</td>
</tr>
<tr>
<td></td>
<td>40 series &quot;B&quot;</td>
<td>3,516,667</td>
</tr>
<tr>
<td><strong>$2.5 million Capital Raising</strong></td>
<td>$0.30 share</td>
<td>8,333,333</td>
</tr>
<tr>
<td><strong>Invatec Vendors/Staff</strong></td>
<td>100% of the technology</td>
<td>28,103,500</td>
</tr>
<tr>
<td><strong>TOTAL ON ISSUE AT COMPLETION</strong></td>
<td></td>
<td>90.1 million</td>
</tr>
<tr>
<td><strong>Patents</strong></td>
<td></td>
<td>10,346,803</td>
</tr>
<tr>
<td><strong>Vendor Milestone 1</strong></td>
<td>(VALIDATION)</td>
<td>6,000,000</td>
</tr>
<tr>
<td><strong>Vendor Milestone 2</strong></td>
<td>(ALGORITHM)</td>
<td>6,000,000</td>
</tr>
<tr>
<td><strong>Vendor Milestone 3</strong></td>
<td>(FDA/TGA)</td>
<td>6,000,000</td>
</tr>
<tr>
<td><strong>ALL MILESTONES ACHIEVED</strong></td>
<td></td>
<td>115.6 million</td>
</tr>
</tbody>
</table>

Subject to relevant Shareholder approvals – anticipated in February 2015